European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

The move will also create 12,000 new jobs across the United States, with 6,500 in construction and 1,000 at “new and expanded ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set ...

Novartis is set to invest $23 billion in US-based manufacturing and research and development (R&D) over the next five years, ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

Swiss and French pharmaceutical companies Novartis and Sanofi argue that the EU should adjust its drug prices to better align with those in the US.